科济药业-B(02171)今日盘中大涨5.01%,引发市场高度关注。
公司旗舰产品舒瑞基奥仑赛注射液是一种靶向Claudin18.2蛋白的自体CAR-T细胞疗法,近期在中国进行的一项关键II期临床试验CT041-ST-01取得阳性结果。该试验评估了舒瑞基奥仑赛注射液用于治疗Claudin18.2表达阳性、既往接受过至少2线治疗失败的晚期胃癌/食管胃结合部腺癌的有效性和安全性。试验主要终点显示,与标准治疗相比,该产品组无进展生存期有统计学意义上的显著改善,表明其在提高患者生存获益方面疗效显著。临床数据也表明该产品总体安全性可控。
舒瑞基奥仑赛注射液作为一种潜在全球首创的CAR-T产品,临床阳性结果引发市场对科济药业未来发展前景的乐观预期。不仅验证了公司在肿瘤细胞免疫治疗领域的研发实力和竞争优势,未来也将为公司带来可观的商业回报。目前该产品还在多个临床阶段,未来如果能顺利上市,必将助力公司业绩实现新的增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.